SEC EDGARSEP 171 min read$TBPH

Farnum Rhonda sold $227K of TBPH

Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) sold 13,314 shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.03 ($17.03–$17.03, $0.23M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farnum Rhonda

Published Sep 17, 2026, 9:52 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 17, 2026, 10:01 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TBPH

Neutral

high confidence

Mentioned

$TBPH

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TBPHNeutralLow

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited actionable insight.

Market read

Small insider sale with minimal market impact.

What to watch

Potential upcoming clinical data releases may influence insider sentiment.

Relevance 3/10Novelty 6/10Timing: post‑market 2026-09-15

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TBPHNeutralHigh confidence

Context

Insider sold 13,314 shares for $226,793 via a 10b5-1 plan on 2026-09-15.

Expected impact

Minimal impact; likely no significant price movement.

Evidence & confidence

The sale size (~$227k) is small relative to market cap and disclosed via a pre‑arranged plan, suggesting limited informational content.

Market effects

Sector

No immediate sector impact; insider activity is isolated.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

Company
Theravance Biopharma, Inc.
Biopharma company listed on Nasdaq (TBPH).
Insider
Rhonda Farnum
Senior Vice President, Communications & Medical Affairs.

Read at source ← All news

SEP 28

$ZYMEHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

gurufocus.com3 min

SEP 23

$ZYMEHighAI 8/10

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

finanznachrichten.de2 min

SEP 23

$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min

AUG 10

$TBPHMedAI 8/10

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

tradingview.com2 min

AUG 10

$TBPHHigh

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Revenue increased 11% year-over-year 1 , from $18

SEC EDGAR 8-K6 min

JUL 21

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min